Incyte Co. (NASDAQ:INCY) to Post Q2 2025 Earnings of $1.19 Per Share, William Blair Forecasts

Incyte Co. (NASDAQ:INCY) – Investment analysts at William Blair decreased their Q2 2025 earnings per share estimates for shares of Incyte in a research report issued on Tuesday, April 23rd. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $1.19 for the quarter, down from their previous forecast of $1.23. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $3.85 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.31 EPS and Q4 2025 earnings at $1.35 EPS.

Other equities analysts also recently issued research reports about the company. Stifel Nicolaus boosted their target price on Incyte from $67.00 to $68.00 and gave the stock a “hold” rating in a research note on Wednesday, February 14th. Cantor Fitzgerald began coverage on Incyte in a research note on Tuesday. They issued a “neutral” rating on the stock. Citigroup cut their target price on Incyte from $82.00 to $81.00 and set a “buy” rating on the stock in a research note on Wednesday, February 14th. Bank of America dropped their price objective on Incyte from $69.00 to $67.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 13th. Finally, Truist Financial dropped their price objective on Incyte from $91.00 to $84.00 and set a “buy” rating on the stock in a research note on Wednesday, February 14th. Nine equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.50.

Incyte Price Performance

Shares of NASDAQ INCY opened at $51.74 on Wednesday. Incyte has a twelve month low of $50.27 and a twelve month high of $75.74. The stock’s 50 day moving average price is $57.06 and its 200-day moving average price is $57.78. The company has a market capitalization of $11.62 billion, a PE ratio of 19.52, a PEG ratio of 1.20 and a beta of 0.65. The company has a quick ratio of 3.36, a current ratio of 3.55 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.09). The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Incyte had a net margin of 16.17% and a return on equity of 12.56%. Incyte’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.44 EPS.

Institutional Investors Weigh In On Incyte

Hedge funds and other institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC increased its holdings in shares of Incyte by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 531,625 shares of the biopharmaceutical company’s stock worth $33,381,000 after purchasing an additional 37,932 shares during the period. State of Alaska Department of Revenue increased its stake in Incyte by 13.6% in the third quarter. State of Alaska Department of Revenue now owns 64,309 shares of the biopharmaceutical company’s stock valued at $3,714,000 after acquiring an additional 7,695 shares during the last quarter. Royal Bank of Canada increased its stake in Incyte by 85.3% in the third quarter. Royal Bank of Canada now owns 987,052 shares of the biopharmaceutical company’s stock valued at $57,021,000 after acquiring an additional 454,416 shares during the last quarter. RFG Advisory LLC bought a new position in Incyte in the fourth quarter valued at $206,000. Finally, Raymond James & Associates bought a new position in Incyte in the fourth quarter valued at $2,291,000. Institutional investors own 96.97% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.